Intervention

EGb 761® (Tanakan®)

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

3 shown

Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's DiseaseNCT00500500 · 2005-07-01

TERMINATED

Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisNCT00276341 · 2003-08-26

COMPLETED

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory ComplaintsNCT00276510 · 2002-02-01

COMPLETED

Common conditions

Alzheimer Disease1 Memory Disorders, Age-Related1 Multiple Sclerosis, Relapsing-Remitting1 Retention Disorders, Cognitive1

Leading sponsors

Ipsen3

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

PHASE21

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.